Long-Term follow up after intra-Uterine transfusionS; the LOTUS study

BMC Pregnancy and Childbirth

Volumn 10, Issue , 2010, Pages

  Verduin, Esther P ^a,b   Lindenburg, Irene T M ^b   Smits Wintjens, Vivianne E H J ^b   Van Klink, Jeanine M M ^b   Schonewille, Henk ^a   Van Kamp, Inge L ^b   Oepkes, Dick ^b   Walther, Frans J ^b   Kanhai, Humphrey H H ^b   Doxiadis, Ilias I N ^b   Lopriore, Enrico ^b   Brand, Anneke ^a,b  

^a CENTRAL LABORATORY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNIZATION; ARTICLE; BLINDNESS; BLOOD GROUP; BLOOD SAMPLING; CEREBRAL PALSY; CHILD; FEMALE; FETUS; FOLLOW UP; HEARING LOSS; HEMOLYTIC DISEASE OF THE FETUS AND NEWBORN; HUMAN; INCIDENCE; INTRAUTERINE BLOOD TRANSFUSION; LONG TERM CARE; MICROCHIMERISM; MOTHER; NEUROLOGIC DISEASE; NEWBORN; NEWBORN HEMOLYTIC DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROGENY; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SALIVA ANALYSIS; SURVIVAL RATE; ADOLESCENT; ADULT; COGNITIVE DEFECT; COHORT ANALYSIS; HEARING IMPAIRMENT; METHODOLOGY; PREGNANCY; PRESCHOOL CHILD; PSYCHOMOTOR DISORDER; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLINDNESS; BLOOD TRANSFUSION, INTRAUTERINE; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; COHORT STUDIES; DEAFNESS; ERYTHROBLASTOSIS, FETAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; PREGNANCY; PSYCHOMOTOR DISORDERS; RESEARCH DESIGN; TIME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649523476     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/1471-2393-10-77     Document Type: Article

References (36)

1. Vietor HE, Kanhai HH, Brand A. Induction of additional red cell alloantibodies after intrauterine transfusions. Transfusion 1994, 34:970-974. 10.1046/j.1537-2995.1994.341195065035.x, 7974705.
2. Schonewille H, Klumper FJ, van de Watering LM, Kanhai HH, Brand A. High additional maternal red cell alloimmunization after Rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus. Am J Obstet Gynecol 2007, 196:143-146. 10.1016/j.ajog.2006.10.895, 17306657.
3. Schonewille H, Haak HL, van Zijl AM. RBC antibody persistence. Transfusion 2000, 40:1127-1131. 10.1046/j.1537-2995.2000.40091127.x, 10988317.
4. Poissonnier MH, Brossard Y, Demedeiros N, Vassileva J, Parnet F, Larsen M, Gosset M, Chavinie J, Huchet J. Two hundred intrauterine exchange transfusions in severe blood incompatibilities. Am J Obstet Gynecol 1989, 161:709-713.
5. Weiner CP, Williamson RA, Wenstrom KD, Sipes SL, Widness JA, Grant SS, Estle L. Management of fetal hemolytic disease by cordocentesis. II. Outcome of treatment. Am J Obstet Gynecol 1991, 165:1302-1307.
6. van Kamp IL, Klumper FJ, Oepkes D, Meerman RH, Scherjon SA, Vandenbussche FP, Kanhai HH. Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am J Obstet Gynecol 2005, 192:171-177. 10.1016/j.ajog.2004.06.063, 15672021.
7. van Kamp IL, Klumper FJ, Meerman RH, Oepkes D, Scherjon SA, Kanhai HH. Treatment of fetal anemia due to red-cell alloimmunization with intrauterine transfusions in the Netherlands, 1988-1999. Acta Obstet Gynecol Scand 2004, 83:731-737. 10.1111/j.0001-6349.2004.00394.x, 15255845.
8. Doyle LW, Kelly EA, Rickards AL, Ford GW, Callanan C. Sensorineural outcome at 2 years for survivors of erythroblastosis treated with fetal intravascular transfusions. Obstet Gynecol 1993, 81:931-935.
9. Stewart G, Day RE, Del PC, Whittle MJ, Turner TL, Holland BM. Developmental outcome after intravascular intrauterine transfusion for rhesus haemolytic disease. Arch Dis Child Fetal Neonatal Ed 1994, 70:F52-F53. 10.1136/fn.70.1.F52, 1060990, 8117130.
10. Janssens HM, de Haan MJ, van Kamp IL, Brand R, Kanhai HH, Veen S. Outcome for children treated with fetal intravascular transfusions because of severe blood group antagonism. J Pediatr 1997, 131:373-380. 10.1016/S0022-3476(97)80061-3, 9329412.
11. Hudon L, Moise KJ, Hegemier SE, Hill RM, Moise AA, Smith EO, Carpenter RJ. Long-term neurodevelopmental outcome after intrauterine transfusion for the treatment of fetal hemolytic disease. Am J Obstet Gynecol 1998, 179:858-863. 10.1016/S0002-9378(98)70178-4, 9790359.
12. Grab D, Paulus WE, Bommer A, Buck G, Terinde R. Treatment of fetal erythroblastosis by intravascular transfusions: outcome at 6 years. Obstet Gynecol 1999, 93:165-168. 10.1016/S0029-7844(98)00421-9, 9932548.
13. Harper DC, Swingle HM, Weiner CP, Bonthius DJ, Aylward GP, Widness JA. Long-term neurodevelopmental outcome and brain volume after treatment for hydrops fetalis by in utero intravascular transfusion. Am J Obstet Gynecol 2006, 195:192-200. 10.1016/j.ajog.2005.12.012, 16813754.
14. Nagel HT, de Haan TR, Vandenbussche FP, Oepkes D, Walther FJ. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection. Obstet Gynecol 2007, 109:42-47. 10.1097/01.AOG.0000249611.67873.94, 17197586.
15. Germinal matrix-intraventricular hemorrhage of the premature infant. Neurology of the Newborn 1995, 403-463. Philadelphia: Saunders, Volpe JJ.
16. de Vries LS, Eken P, Dubowitz LM. The spectrum of leukomalacia using cranial ultrasound. Behav Brain Res 1992, 49:1-6. 10.1016/S0166-4328(05)80189-5, 1388792.
17. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, Brotherton T. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978, 187:1-7. 10.1097/00000658-197801000-00001, 1396409, 413500.
18. An international classification of retinopathy of prematurity. Prepared by an international committee. Br J Ophthalmol 1984, 68:690-697. 10.1136/bjo.68.10.690, 1040449, 6548150.
19. Touwen BC, Hempel MS, Westra LC. The development of crawling between 18 months and four years. Dev Med Child Neurol 1992, 34:410-416. 10.1111/j.1469-8749.1992.tb11453.x, 1592193.
20. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE). Dev Med Child Neurol 2000, 42:816-824.
21. van der Meulen BF, Ruiter SAJ. Bayley Scales of Infant Development-II, Netherlands version. 2002, Lisse, Swets Test Publishers, Lutje Spelberg HC, Smrkovsky M.
22. Wechsler D. Wechsler Preschool and Primary Scale of Intelligence - Third Edition (WPPSI-III-NL). 2002, TX, The Psychological Corporation.
23. Wechsler D. Wechsler Intelligence Scale for Children. 1991, TX, Psychological Corporation, Third.
24. van Widenfelt BM, Goedhart AW, Treffers PD, Goodman R. Dutch version of the Strengths and Difficulties Questionnaire (SDQ). Eur Child Adolesc Psychiatry 2003, 12:281-289. 10.1007/s00787-003-0341-3, 14689260.
25. Vogels T, Verrips GH, Koopman HM. TACQOL manual. Parent Form and Child Form. 2000, Leiden, Leiden Center for Child Health and Pediatrics LUMC-TNO.
26. Fekkes M, Kamphuis RP, Ottenkamp J, Verrips E, Vogels T, Kamphuis MM, Verloove-Vanhorick SP. Health-related quality of life in young adults with minor congenital heart disease. Psychol Health 2001, 16:239-250.
27. Noizat-Pirenne F, Tournamille C, Bierling P, Roudot-Thoraval F, Le Pennec PY, Rouger P, Ansart-Pirenne H. Relative immunogenicity of Fya and K antigens in a Caucasian population, based on HLA class II restriction analysis. Transfusion 2006, 46:1328-1333. 10.1111/j.1537-2995.2006.00900.x, 16934068.
28. Picard C, Frassati C, Basire A, Buhler S, Galicher V, Ferrera V, Reviron D, Zappitelli JP, Bailly P, Chiaroni J. Positive association of DRB1 04 and DRB1 15 alleles with Fya immunization in a Southern European population. Transfusion 2009, 49:2412-2417. 10.1111/j.1537-2995.2009.02369.x, 19702653.
29. Reviron D, Dettori I, Ferrera V, Legrand D, Touinssi M, Mercier P, de MP, Chiaroni J. HLA-DRB1 alleles and Jk(a) immunization. Transfusion 2005, 45:956-959. 10.1111/j.1537-2995.2005.04366.x, 15934994.
30. Suciu-Foca N, Reed E, Rohowsky C, Kung P, King DW. Anti-idiotypic antibodies to anti-HLA receptors induced by pregnancy. Proc Natl Acad Sci USA 1983, 80:830-834. 10.1073/pnas.80.3.830, 393474, 6600840.
31. Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization in female apheresis donors. Transfusion 1999, 39:103-106. 10.1046/j.1537-2995.1999.39199116901.x, 9920173.
32. Regan J, Monteiro F, Speiser D, Kalil J, Pouletty P, Buelow R. Pretransplant rejection risk assessment through enzyme-linked immunosorbent assay analysis of anti-HLA class I antibodies. Am J Kidney Dis 1996, 28:92-98. 10.1016/S0272-6386(96)90136-5, 8712228.
33. Adams KM, Lambert NC, Heimfeld S, Tylee TS, Pang JM, Erickson TD, Nelson JL. Male DNA in female donor apheresis and CD34-enriched products. Blood 2003, 102:3845-3847. 10.1182/blood-2003-05-1570, 12869496.
34. Lapaire O, Hosli I, Zanetti-Daellenbach R, Huang D, Jaeggi C, Gatfield-Mergenthaler S, Hahn S, Holzgreve W. Impact of fetal-maternal microchimerism on women's health--a review. J Matern Fetal Neonatal Med 2007, 20:1-5. 10.1080/14767050601144834, 17437192.
35. Mosca M, Giuliano T, Curcio M, Doveri M, De FF, Tani C, Bazzichi L, Bombardieri S. Comparison of real-time PCR and nested PCR for the detection of Y chromosome sequences in the peripheral blood mononuclear cells of patients with systemic sclerosis. Ann Rheum Dis 2009, 68:155-156. 10.1136/ard.2008.089821, 19088263.
36. Invernizzi P, Pasini S, Selmi C, Gershwin ME, Podda M. Female predominance and X chromosome defects in autoimmune diseases. J Autoimmun 2009, 33:12-16. 10.1016/j.jaut.2009.03.005, 19356902.